



This is a repository copy of *The challenge of assessing impaired awareness of hypoglycaemia in diabetes in the era of continuous glucose monitoring: a narrative review of evidence and translation into clinical practice.*

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/223941/>

Version: Published Version

Article:

Berry, S.A. orcid.org/0009-0007-9100-8778, Liarakos, A.L. orcid.org/0000-0003-1713-3064, Koutroukas, V. orcid.org/0000-0001-6120-8057 et al. (3 more authors) (2025) The challenge of assessing impaired awareness of hypoglycaemia in diabetes in the era of continuous glucose monitoring: a narrative review of evidence and translation into clinical practice. *Diabetes Obes Metab.* ISSN 1462-8902

<https://doi.org/10.1111/dom.16284>

Reuse

This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here:

<https://creativecommons.org/licenses/>







Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

The challenge of assessing impaired awareness of hypoglycaemia in diabetes in the era of continuous glucose monitoring: A narrative review of evidence and translation into clinical practice

Simon A. Berry MBChB (Hons)¹  | Alexandros L. Liarakos MBBS^{2,3}  |
Vaios Koutroukas MBBS⁴  | Pratik Choudhary MD⁴  | Emma G. Wilmot PhD^{2,3}  |
Ahmed Iqbal PhD¹ 

¹Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, Sheffield, UK

²Department of Diabetes and Endocrinology, University Hospitals of Derby and Burton NHS Foundation Trust, Royal Derby Hospital, Derby, UK

³School of Medicine, Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham, UK

⁴Diabetes Research Centre, University of Leicester, Leicester, UK

Correspondence

Emma G. Wilmot, Department of Diabetes and Endocrinology, University Hospitals of Derby and Burton NHS Foundation Trust, Royal Derby Hospital, Derby, UK.

Email: emma.wilmot@nottingham.ac.uk

Abstract

Iatrogenic hypoglycaemia remains a major barrier in diabetes care. Over time, and with repeated hypoglycaemic episodes, the physiological responses to hypoglycaemia can become blunted, resulting in impaired awareness of hypoglycaemia (IAH). In IAH, the onset of cognitive dysfunction precedes the onset of autonomic symptoms, often preventing appropriate self-treatment, thus increasing the frequency of severe hypoglycaemia (SH). Historically, IAH has been assessed with questionnaires, such as the Gold and Clarke scores, which were developed in the 1990s. A stepwise change in diabetes management in the last few decades has been the deployment of continuous glucose monitoring (CGM). CGM allows people with diabetes to set alarms that can warn them of hypoglycaemia or even impending hypoglycaemia, thus providing a degree of 'technological' awareness. This creates a challenge in assessing awareness status, as people may be alerted to low-sensor glucose events before they experience any symptoms. CGM also allows the introduction of new measures of hypoglycaemia exposure such as time below range, which might complement traditional methods of risk assessment. These changes in the field prompt a need for reassessment of the measures of IAH. This narrative review evaluates the current epidemiology of SH and IAH, explores different measures of IAH, and evaluates the relationship between CGM metrics, IAH and SH. We conclude that a clinical approach involving traditional questionnaires, or newer updated alternatives such as the Hypo A-Q awareness scale, combined with CGM metrics and clinical assessment of human factors is recommended in the absence of a clearly superior measure.

KEYWORDS

continuous glucose monitoring, diabetes complications, hypoglycaemia, patient reported outcomes, type 1 diabetes, type 2 diabetes

This is an open access article under the terms of the [Creative Commons Attribution](https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2025 The Author(s). *Diabetes, Obesity and Metabolism* published by John Wiley & Sons Ltd.

1 | INTRODUCTION

More than a century from the discovery of insulin, iatrogenic hypoglycaemia remains a major barrier in diabetes care.¹ In people with diabetes, hypoglycaemia is the consequence of the interaction between relative insulin excess from treatment and compromised physiological defences against falling plasma glucose.¹ Hypoglycaemia is the critical limiting factor in intensive glycaemic control in diabetes, which is essential to prevent long term complications.² Severe hypoglycaemia (SH) can occur if hypoglycaemia remains untreated, and is defined as hypoglycaemia leading to acute severe cognitive impairment requiring external assistance for recovery.³ SH can lead to death, with an estimated 8% of deaths of people with type 1 diabetes (T1D) followed-up from childhood up to the age of 55 years of age attributed to hypoglycaemia.⁴ Mortality rates of people with T1D (pwT1D) at a later age of onset are less evidenced in the literature.

In normal physiology, the counterregulatory response to hypoglycaemia is activated at glucose levels of ~ 3.9 mmol/L, followed by the manifestation of autonomic symptoms at ~ 3.3 mmol/L and neuroglycopenic symptoms at ~ 2.8 mmol/L.⁵ Impaired awareness of hypoglycaemia (IAH) is the result of attenuated counterregulatory responses and reduced perception of symptoms to hypoglycaemia.⁶ Antecedent hypoglycaemia blunts the response to subsequent hypoglycaemia,⁷ leading to lower glycaemic thresholds for adrenaline release and initiation of autonomic symptoms than in people with normal awareness of hypoglycaemia (NAH).⁸ In IAH, the onset of cognitive dysfunction precedes the onset of symptoms, impairing the coordination and execution of self-treatment, thus increasing the frequency of SH six-fold in T1D and 17-fold in insulin-treated type 2 diabetes (T2D).^{9,10} IAH exists on a spectrum, and awareness of hypoglycaemia and strength of counter-regulation is affected day-to-day by factors such as the time of day, sleep and exercise.^{11,12} IAH is also not a single entity, rather a clinical syndrome covering a heterogeneous group of pathophysiological defects, all of which culminate in reduced awareness of hypoglycaemia symptoms. Described defects that contribute to counter-regulatory impaired awareness include early loss of the glucagon response to hypoglycaemia,¹³ attenuated sympathoadrenal activity,⁷ altered central glucose sensing,¹⁴ and disruption of arousal and decision-making centres of the brain.¹⁵ Increasingly IAH is seen in older adults with T1D with multiple comorbidities,¹⁶ reflecting two peaks of prevalence: the first in those with a recent onset of diabetes and a second in those with a longer duration of diabetes.¹⁷ IAH can be reversible and thus, identification of IAH is important to stratify a person with diabetes to the correct treatment.^{18–21}

Historically, IAH has been assessed with questionnaires developed in the 1990s. A GOLD or Clarke score ≥ 4 have been used as the diagnostic cut-off.^{22,23} Other scoring systems have since been developed.^{24–26} A stepwise change in diabetes management in the last few decades has been the ongoing development of continuous glucose monitoring (CGM).²⁷ CGM can be set with alarms to warn a person with diabetes that the blood glucose level has dropped or is predicted to drop into the hypoglycaemic range.²⁸ The person with diabetes may receive an alarm at a glucose level higher than when

they typically experience symptoms and so may not be sure of what symptoms they get, blurring the lines between symptomatic awareness and 'technological' awareness. This may alter how pwT1D responds to questionnaires designed to assess awareness of hypoglycaemia (Figure 1). Furthermore, CGM allows the introduction of new measures of hypoglycaemia exposure such as time below range (TBR), which might complement traditional methods of risk assessment.²⁹

These changes in the field prompt a need for reassessment of the measures of IAH. The aim of this narrative review is to identify the best tool or combination of tools to assess for IAH and the risk of SH in clinical practice based on research evidence. To achieve this, we evaluated the current prevalence of IAH and incidence of SH, explored the background of the different measures of IAH, detailed their components and reviewed both their historic and current evidence in terms of real-world data and response to experimental hypoglycaemia. Finally, we evaluated the relationship between CGM metrics, IAH and SH. We used the keywords 'severe hypoglycemia', 'impaired awareness of hypoglycemia', 'hypoglycemia awareness' and 'hypoglycemia unawareness,' with synonyms, alone and in combination with each other and with keywords such as 'prevalence', 'epidemiology', 'incidence', 'validation' and 'score OR questionnaire' to retrieve available literature data from PubMed from inception until August 2024. The reference list from relevant papers was explored for further references and refined within the study group.

2 | THE PREVALENCE OF IAH AND SEVERE HYPOGLYCAEMIA—HAS IT CHANGED?

The prevalence of IAH in T1D has historically been quoted as around 25%, based on retrospective case reviews from the 1980s and 1990s,⁹ whereas the prevalence of IAH in insulin-treated T2D has been estimated to be around 10%.¹⁰ However, when individuals with T1D and T2D were matched for duration of treatment with insulin in one study, hypoglycaemia rates were comparable.³⁰ Multiple studies over the last few decades have sought to update the estimated prevalence given improvements in clinical care and measures that reduce hypoglycaemia, such as structured education, newer insulin analogues, CGM and automated insulin delivery (AID) systems (Figure 2). Since 2020, studies have shown the estimated prevalence of IAH in T1D has decreased to between 15% and 18%. Exceptions were observational data from a unique patient population in a single tertiary centre, where the prevalence was estimated to be 33.3%, and data from the T1D Exchange, which estimated prevalence at 30.7% in a cohort of individuals historically shown to be highly engaged and more likely to achieve glycaemic targets.^{31–35} In insulin-treated T2D, the estimated prevalence in studies since 2020 has been between 9.7% and 13.7%.^{36–38} There is considerable heterogeneity in the estimated prevalence between different studies. Reasons include the different methods used for diagnosis of IAH and the different baseline characteristics of studied populations.⁹ When studied in the same centre, the prevalence has been shown to have reduced over time.³³ Of those in the cohort with data from all time points, the proportion of

FIGURE 1 Illustration of the symptomatic presentation of hypoglycaemia in people with impaired awareness of hypoglycaemia before and after the introduction of Continuous Glucose Monitoring (CGM). Created with biorender.com.




FIGURE 2 Prevalence of Impaired Awareness of Hypoglycaemia (IAH) in different studies over time in type 1 diabetes (blue) and type 2 diabetes (red). Please see Table S1 for data from individual studies.

participants with persistent IAH dropped, supporting the idea that IAH is dynamic and reversible.³³

The second question to be answered is whether the incidence of SH has changed over time. Evidence from randomized controlled trials (RCTs) (Table S2) indicates that CGM decreases the incidence of biochemical and severe hypoglycaemia when compared with self-monitoring of blood glucose (SMBG) in pwT1D and a history of IAH and/or SH.³⁹ Real-world studies in Belgium, Norway and the United Kingdom demonstrated significant reductions in the incidence of SH after initiation of CGM, indicating that the benefits observed in RCTs are also applicable to real-world use.^{40–42}

Therefore, given the increasing CGM use, one would expect observational data to show a marked reduction in the incidence of SH. Heterogeneity in the observational data makes it difficult to exactly quantify the incidence but recent studies demonstrate that between 6% and 20% of pwT1D reported an episode of SH in the last year (Figure 3).^{32,33,35,42,43} In people with insulin-treated T2D, studies since 2020 have reported that between 0.6% and 31.6% of people had an episode of SH in the last year (Figure 3).^{36,37,44} One difficulty in drawing conclusions is the SH reporting methodology, because some studies report number of episodes per person year, whereas other studies report proportion of people with an episode of SH in




FIGURE 3 Proportion of participants with an episode of Severe Hypoglycaemia (SH) in last year – type 1 diabetes in blue, type 2 diabetes in red. Please see Table S1 for data from individual studies.

the preceding year. These data are not easily comparable, as the incidence of SH per patient is not normally distributed but skewed towards more frequent episodes in high-risk individuals.⁴⁵ Furthermore, the reporting of SH is subject to considerable recall bias, particularly when recorded retrospectively.⁴⁶ Other reasons for heterogeneity include different definitions of SH used between studies, and large inter-regional differences.^{46,47} Additionally, legal factors can influence participant reporting of episodes—there was a 55% drop in the reported incidence of SH after changes in driving laws in the European Union.⁴⁸

Another important question is whether the risk of SH remains high with IAH when compared with people with NAH after CGM initiation. Similarly to older studies,^{9,10} a recent cross-sectional observational study demonstrated that an increased risk of SH in IAH persists in T1D when compared with those with intact awareness despite the use of CGM.⁴⁹ IAH, as identified by the Gold, Clarke and Pedersen-Bjergaard questionnaires, was associated with 6-, 4.6- and 5.8-fold increased risk of SH ($p = 0.001, 0.004$ and 0.013), respectively. In a further study by the same group, persistent SH despite CGM with alarms and AID systems was found to be influenced by participants' beliefs about prioritizing hyperglycaemia avoidance, suggesting that human factors may be responsible.³¹

Older studies, such as the DCCT trial, showed that low HbA1c was associated with higher rates of SH.² However, multiple studies in the last decade have shown that this link has uncoupled. In the HAT study, there was no significant association between HbA1c and SH in both people with T1D and insulin-treated T2D.⁴⁷ Furthermore, both

the GOLD randomized crossover trial and a post-hoc analysis of the DIAMOND and HypoDE studies showed a dissociation between percent of time in hypoglycaemia and low HbA1c when CGM was used compared with SMBG.^{50,51}

In summary, the overall data indicate that the prevalence of IAH and incidence of SH in T1D is decreasing, but the incremental risk of SH in people with IAH over NAH remains a significant problem that needs addressing in clinical practice despite the use of new technologies such as CGM and AID systems.

3 | MEASURES OF IMPAIRED AWARENESS OF HYPOGLYCAEMIA

3.1 | Traditional measures of IAH

Several different tools and questionnaires have been developed to assess and diagnose IAH. The predominant tools that have been used clinically and in research are the Gold Score, Clarke Score, Pedersen-Bjergaard Score, DAFNE tool, Hypo A-Q Impaired Awareness Subscale and the HYPO score.^{22–26,52} Modified versions of the Clarke Score and Pedersen-Bjergaard Score now exist. They all ask different questions and vary in the time to complete, inclusion of past frequency of hypoglycaemia and methods of validation (Table 1). Validation can take multiple forms including real-world comparison with rates of SH, discrimination analyses between IAH and normal awareness of hypoglycaemia (NAH) participants, and comparison with

TABLE 1 Comparison of questionnaire methods used for diagnosis of IAH.

	Gold	Minimally modified Clarke (MMCHS)	Updated Pedersen-Bjergaard	DAFNE	HYPQ	Hypo A-Q impaired awareness subscale
Year of publication	1994	2012 (original 1995)	2022 (original 2003)	2002	2004	2016
No. of questions	1	8	1	1	4 weeks of data	5
Frequency of hypoglycaemia	No	Yes	No	No	Yes	No
Categories	IAH ≥ 4 NAH < 4 (indeterminate = 3)	IAH ≥ 4 or $1 \times U$ NAH < 4	IAH "Occasionally" or "Never" Intermediate "Usually" Normal "Always"	IAH < 3 mmol/L NAH ≥ 3 mmol/L	No concern ≤ 423 Moderate issues 424–1046 Severe issues ≥ 1047	IAH ≥ 12 NAH < 12
Advantages	<ul style="list-style-type: none"> • Quick and simple question • Used extensively for >20 years • Used as Gold standard for many research trials • Validated in hyper-insulinaemic hypoglycaemic clamps • Demonstrated improvement after intervention 	<ul style="list-style-type: none"> • Used extensively • Used as Gold standard for many research trials • Validated with high AUC in hyper-insulinaemic hypoglycaemic clamps • Validated pre- and post-intervention • Demonstrated improvement after intervention 	<ul style="list-style-type: none"> • Quick and simple question • Three categories incorporating spectrum of disease 	<ul style="list-style-type: none"> • Quick and simple question • Cut-off corresponds with Level 2 hypoglycaemia i.e. threshold of neuroglycopenic symptoms • Demonstrated improvement after intervention 	<ul style="list-style-type: none"> • Useful research tool 	<ul style="list-style-type: none"> • Differentiates nocturnal from diurnal hypoglycaemia • Validated against clamp, CGM and other IAH measures • Compliant with FDA guidelines • Validated in type 2 diabetes
Disadvantages	<ul style="list-style-type: none"> • Dichotomous grading leads to inconsistencies when IAH is more borderline 	<ul style="list-style-type: none"> • Cut-off not consistent with IHSG classifications of hypoglycaemia • Inclusion of frequency of severe hypoglycaemia susceptible to improvements with new treatments • Can lead to IAH diagnosis when awareness intact 	<ul style="list-style-type: none"> • Over-estimates prevalence of IAH (addressed to some extent in updated version) • Not validated alone in hyperinsulinaemic-hypoglycaemic clamps 	<ul style="list-style-type: none"> • Not validated 	<ul style="list-style-type: none"> • Used predominantly as measure of hypoglycaemia severity • Resource and time intensive 	<ul style="list-style-type: none"> • Tested on relatively few people compared with more established measures

Abbreviations: AUC, area under the curve; CGM, continuous glucose monitoring; IAH, impaired awareness of hypoglycaemia; IHSG, International Hypoglycemia Study Group; NAH, normal awareness of hypoglycaemia.

a. GOLD Score: “Do you know when your hypos are commencing?”

Always aware 1 2 3 4 5 6 7 Never Aware

b. DAFNE Tool: “Do your symptoms of hypoglycaemia usually occur at a blood glucose level of:

- Greater than or equal to 3 mmol/L
- **Less than 3 mmol/L**
- **Never**”

c. Updated Pedersen-Bjergaard Score: “Can you feel when your blood sugar is low?”

- Always
- **Usually**
- **Occasionally**
- **Never**

d. Minimally Modified Clarke Hypoglycaemia Survey (MMCHS)

1. Pick the category that best describes you (one only)

- I always have symptoms when my blood sugar is low (A)
- I sometimes have symptoms when my blood sugar is low (R)
- I no longer have symptoms when my blood sugar is low (R)

Factor 12. Have you lost some of the symptoms that used to occur when your blood sugar was low **Yes (R)** No (A)

3. In the past 6 months, how often have you had hypoglycaemic episodes, where you might feel confused, disorientated, or lethargic and were unable to treat yourself

- Never (A) **Once or Twice (R)** **Every other month (R)** **Once a month (R)** **More than once a month (R)**

Factor 2

4. In the past year, how often have you had hypoglycaemic episodes, where you were unconscious or had a seizure and needed glucagon or intravenous glucose

- Never (A) **1 Time (R)** **2 times (R)** **3 times (R)** **4 times (R)** **5 times (R)** **6 times (R)** **7 times (R)** **8 times (R)**
- 9 times (R)** **10 times (R)** **11 times (R)** **12 or more times (U)**

5. How often in the last month have you had readings <3.5 mmol/L with symptoms

- Never 1-3 times 1 time/week 2 to 3 times/week 4 to 5 times/week Almost daily

6. How often in the last month have you had readings <3.5 mmol/L without any symptoms

- Never 1-3 times 1 time/week 2 to 3 times/week 4 to 5 times/week Almost daily

(R = answer to 5 < answer to 6, A = answer to 5 ≤ answer to 6)

7. How low does your blood sugar need to go before you feel symptoms

- 3.4-3.8 mmol/L (A) 2.8-3.3 mmol/L (A) **2.2-2.7 mmol/L (R)** **<2.2 mmol/L (R)**

8. To what extent can you tell by your symptoms that your blood sugar is low

- Never (R)** **Rarely (R)** **Sometimes (R)** Often (A) Always (A)

e. Hypo A-Q Awareness Subscale:

	Never	Rarely	Sometimes	Often	Always
7. I have symptoms when my blood glucose is low	<input type="checkbox"/> 4	<input type="checkbox"/> 3	<input type="checkbox"/> 2	<input type="checkbox"/> 2	<input type="checkbox"/> 0
8. I ‘just know’ when I am going hypo by the way that I feel	<input type="checkbox"/> 4	<input type="checkbox"/> 3	<input type="checkbox"/> 2	<input type="checkbox"/> 2	<input type="checkbox"/> 0
10. Other people recognise I am hypo before I do	<input type="checkbox"/> 0	<input type="checkbox"/> 1	<input type="checkbox"/> 2	<input type="checkbox"/> 3	<input type="checkbox"/> 4
	Strongly disagree	Disagree	Neither agree nor disagree	Agree	Strongly agree
11. I am less aware of my hypos coming on than I used to be	<input type="checkbox"/> 0	<input type="checkbox"/> 1	<input type="checkbox"/> 2	<input type="checkbox"/> 3	<input type="checkbox"/> 4
12. I have lost symptoms I used to have when my blood glucose is low	<input type="checkbox"/> 0	<input type="checkbox"/> 1	<input type="checkbox"/> 2	<input type="checkbox"/> 3	<input type="checkbox"/> 4

FIGURE 4 (A–C) Methods consisting of one question for assessing hypoglycaemia awareness status (A) Gold score (B) DAFNE tool (C) Updated Pedersen-Bjergaard Score. Red denotes scores diagnostic of impaired awareness or loss of awareness in the Pedersen-Bjergaard method, yellow denotes intermediate awareness.^{22,24,61} (D) Minimally Modified Clarke Questionnaire – ≥4 R Impaired Awareness, ≤3 aware, 1 U is unawareness. Factor 1, representing assessment of awareness, in white background. Factor 2, representing the assessment of hypoglycaemia exposure, in grey background.²³ (E) Hypo A-Q Awareness Subscale—Figure adapted from the version available at <https://eprovide.mapi-trust.org/instruments/hypoglycaemia-awareness-questionnaire>. Accessed 21.10.2024.

hyperinsulinaemic-hypoglycaemic clamp study-related metrics. In hyperinsulinaemic-hypoglycaemic clamp studies, insulin and glucose infusions are used to lower the blood glucose to set targets to allow comparison between participant symptom scores, endogenous glucose production and counterregulatory hormone response.⁵³ In real world, the depth and the duration of hypoglycaemic episodes can vary, whereas clamp studies allow for assessment of physiological responses in a controlled experimental setting.

The Gold score was developed in 1994 as a tool to categorize hypoglycaemia awareness in pWT1D, in a study prospectively investigating the frequency of hypoglycaemia in people with IAH.²² The score consists of a single question with participants asked to score between 1 and 7 on a Likert scale, with a score of ≥ 4 deemed as diagnostic of IAH (Figure 4A). In the original study, IAH was defined at a score of 4–7 as these scores were predominantly associated with neuroglycopenic rather than autonomic symptoms.

The Clarke score was developed in 1995 as a classification tool for hypoglycaemia awareness in people with insulin-treated diabetes, in a study prospectively investigating the frequency and severity of hypoglycaemia²³ (Figure 4D). Each question is answered with “R” for reduced awareness or “A” for normal awareness: IAH is defined as ≥ 4 “R” responses while NAH is ≤ 2 “R” responses. In the original questionnaire, if a person reports 12 or more SH episodes in the last year, they are automatically categorized as hypoglycaemia unaware, even if symptoms are intact. A minimally modified version of the Clarke hypoglycaemia survey (MMCHS) has been established, which updated question 4 to the current definition of SH, and reduced the blood glucose threshold for questions 5 and 6 to 3.5 mmol/L from 3.9 mmol/L.⁵⁴ Importantly, the Clarke score incorporates two separate factors – factor 1 includes an assessment of hypoglycaemia awareness, whilst factor 2 questions assess hypoglycaemia exposure and risk of SH.⁵⁵

The Pedersen-Bjergaard score was developed to assess hypoglycaemia awareness in a study examining recall of SH in people with T1D.²⁶ It consists of a single question and differs from the other scores by classifying people into three groups – normal awareness, impaired awareness and unawareness (Figure 4C). A criticism of the score was that it overestimated the prevalence of IAH. For example, in data by Geddes et al. (2007), the prevalence of IAH was 62.5% with Pedersen-Bjergaard compared with 24% with the Gold score,⁵⁶ and Gandhi et al. (2021) reported the prevalence of IAH at 61% with Pedersen-Bjergaard compared with 19% with the Gold score.⁵⁷ Meanwhile, Clarke and Gold scores consistently correlate with each other to a moderate-to-high degree.^{56,58,59} The original authors of the Pedersen-Bjergaard score argue that the three categories give a more nuanced grading of IAH, with impaired awareness associated with a fivefold–sixfold increased rate of SH compared with NAH, and unawareness associated with a 10- to 20-fold increased rate of SH.⁶⁰ They have also argued that the method has been misunderstood and misused in other studies, with the unaware group better aligning with the impaired awareness groups from the Gold and Clarke scores.

In 2022, the Pedersen-Bjergaard method was updated to change the category names to normal awareness, intermediate awareness and unawareness.⁶¹ When the Pedersen-Bjergaard score is modified

so that “occasionally” and “never” represent impaired awareness, a moderate or high correlation has been demonstrated with the Gold and Clarke score.^{56,57,61} The score has been validated in participants with clamp-induced hypoglycaemia in combination with the Gold and Clarke scores but not in a head-to-head comparison.⁶²

Both the Clarke and Gold Scores have been found to have a strong negative correlation with adrenaline and symptom response in hyperinsulinaemic-hypoglycaemic clamp studies, strengthening their evidence base.⁵⁸ However, in one study, 32% of participants were classified inconsistently by Clarke versus the Gold scores. The classification accuracy increased in both extremes of hypoglycaemia awareness.⁵⁸ Recent analyses of the MMCHS have suggested that the diagnostic threshold for IAH may have changed over time.⁵⁵ Improvements in the Clarke score after using CGM might be driven by reduction in SH rather than improvements in symptomatic awareness. The optimal operating point of the Clarke score based on a clamp study from 2023 would be ≥ 5 in contrast to the original cut-off of 4.⁶³ Alternatively, a score ≥ 2 comprising only questions 1, 2, 5/6, 7, 8 might be better at discriminating IAH from NAH than an overall score of ≥ 4 .⁵⁵

It is important to note that these scores of IAH have only been formally validated in pWT1D and not in T2D, yet multiple studies have used the Gold, Clarke and Pedersen-Bjergaard scores to quantify IAH in people with T2D (pwT2D) (Figure 1). A survey-based study by Ang et al. (2023) explored the use of Gold and Clarke scores in pwT2D on insulin and impaired awareness with good correlation with each other, suggesting a cut-off ≥ 4 for Gold and ≥ 2.5 for the 5-item MMCHS but no studies have validated them against clamp-induced hypoglycaemia in T2D.³⁸

3.2 | DAFNE score

The DAFNE programme (2002) is the main structured educational intervention for pWT1D in the UK.²⁴ As part of a 12-month follow-up study, hypoglycaemia awareness status was assessed based on the participants' response to what level of glucose they reported hypoglycaemic symptoms: those reporting symptoms at < 3 mmol/L or absence of symptoms was categorized as having IAH, while those reporting symptoms at ≥ 3 mmol/L were categorized as having intact awareness of hypoglycaemia. This cut-off corresponds with the threshold between Level 1 and Level 2 hypoglycaemia³ and blood concentrations at which cognitive impairment begins.⁶⁴ In the study, those with IAH were 4 times more likely to have had an episode of SH in the last year than those without. The tool has the benefit of being a quick and simple question but no validation against other established measures of hypoglycaemia awareness or clamp-induced hypoglycaemia has been completed.

3.3 | HYPO score

The HYPO score was developed in 2004 as an objective measure of quantifying SH and glucose lability in people with diabetes who were

being considered for islet transplantation.⁵² The score is composed of two parts. The first part includes the patients' self-reported hypoglycaemic episodes requiring third-party assistance, glucagon or ambulance attendance from the last year. The second part is a questionnaire about the number of documented hypoglycaemic episodes (<2.5 and 2.5–2.9 mmol/L). These data are collected over 4 weeks, with more points allocated for fewer or absent symptoms. The correlation with the history of previous-year recalled SH and the 4-week recorded HYPO score was statistically significant but weak ($r = 0.335$, $p < 0.0001$).⁶⁵ In a clamp study aimed at validating clinical metrics of IAH, the HYPO score predicted the hypoglycaemia symptom response (AUC 0.79) but the Clarke score performed better (AUC 0.81).⁶⁶ The HYPO score has been used since in research, predominantly as a measure of hypoglycaemic severity.⁶³ However, it is a time-consuming and resource-intensive method for both the participant during the 4-week monitoring period and for the clinician interpreting the raw data.⁶⁵

3.4 | Hypo A-Q

The Hypoglycaemia Awareness Questionnaire (Hypo A-Q) was developed in 2016 as a measure of hypoglycaemia awareness and problematic hypoglycaemia, with three different subscales reflecting hypoglycaemia awareness, symptom level and symptom frequency.²⁵ The questionnaire was designed through exploratory and cognitive debriefing with pwT1D and IAH, modified by diabetologists and psychologists, and then underwent preliminary validation with a cohort of 120 adults with T1D, half of whom had IAH (Figure 4E). It is the only impaired awareness questionnaire that has been designed to meet US Food and Drug Administration (FDA) patient-reported outcome measure (PROM) standards.⁶⁷

Convergent validity was assessed by comparing the HypoA-Q 'impaired awareness' subscale against Gold and Clarke questionnaire scores, showing good correlation (Gold $r_s = 0.75$, $p < 0.01$; Clarke $r_s = 0.76$, $p < 0.01$). Divergent validity was assessed by comparing the HypoA-Q impaired awareness subscale against diabetes-related distress (PAID total score), diabetes duration and HbA1c. Known-groups validity evaluation demonstrated that the 'hypoglycaemia awareness' subscale (questions 7, 8, 10, 11, 12) and the questions related to the frequency of SH (questions 2a, 4b, 4c) distinguished between maintained and impaired awareness as defined by Gold score.

The above results were reproduced during a study that evaluated the validity of the Hypo A-Q against hyperinsulinaemic-hypoglycaemic clamp and CGM metrics.⁶³ The 'awareness subscale' showed significant differences between participants with intact and those with impaired awareness, which correlated with differences in Clarke ($r = 0.72$, $p < 0.001$), HYPO score ($r = 0.60$, $p < 0.001$), CGM TBR ($r = 0.53$, $p < 0.01$), adrenaline ($r = -0.68$, $p < 0.001$) and autonomic symptom responses ($r = -0.53$, $p < 0.05$) between the two groups. The researchers further suggested a cut-off threshold of ≥ 12 to identify people with impaired awareness based on correlation with a blunted adrenaline response during clamp-induced hypoglycaemia.

In addition, the HypoA-Q score has uniquely undergone validation for assessing awareness of hypoglycaemia in pwT2D treated with insulin.⁶⁸

A novel feature of the Hypo A-Q score is the differentiation between nocturnal and diurnal hypoglycaemia. PwT1D involved in the design of the Hypo A-Q questionnaire highlighted the differences in symptom presentation between day and night, driving its incorporation into the questionnaire.²⁵ The Hypo A-Q questionnaire, whilst novel, has only been validated in small numbers; further studies are needed. Consisting of only five questions, it is short enough to use as a clinical and research tool.

4 | THE USE OF CGM TO PREDICT FUTURE SEVERE HYPOGLYCAEMIA

CGM has become an important part of diabetes management providing useful insights into glucose levels, glycaemic variability and hypoglycaemia. In clinical practice, TBR derived from CGM has become a key metric for the assessment of hypoglycaemia exposure and burden.⁶⁹ The International Consensus on Time in Range recommends that <4% of time is spent <3.9 mmol/L and <1% of time is spent <3.0 mmol/L.⁷⁰ An individual with several short hypoglycaemic episodes may have similar TBR to a person who has a single prolonged episode.⁷¹ However, a hypoglycaemic episode lasting under 15 minutes does not count towards TBR on CGM. This means that there is a risk of underappreciation of an individual's true hypoglycaemia exposure if TBR is used alone without a holistic view of daily events that could indicate potential risks and problematic behaviours. Human factors such as prioritizing hyperglycaemia avoidance, normalizing asymptomatic hypoglycaemia and minimizing hypoglycaemia concerns have been demonstrated to increase the risk of SH by driving self-management decisions including excess or early insulin bolusing and insulin stacking.⁷²

An important question is whether CGM metrics such as TBR can be used to assess IAH and/or predict future SH. Several studies have sought to answer the question of whether CGM metrics correlate with traditional measures of IAH such as the Clarke score. Vieira et al. (2022) showed that people with IAH, as assessed by Clarke score, had a significantly higher TBR and mean duration of hypoglycaemia compared with the other groups.⁷³ The mean duration of hypoglycaemia was found to be an independent predictor of Clarke scores and a mean duration of hypoglycaemia ≥ 106.5 min showed 84.6% sensitivity and 64.4% specificity for IAH. A further cross-sectional observational study of 99 pwT1D showed that IAH was associated with greater %CGM values <3.9 mmol/L and <3.0 mmol/L compared with NAH, and that this directly correlated to increasing Clarke scores. Importantly, IAH was related to more events lasting ≥ 20 minutes.⁷⁴ Henriksen et al. (2018), conducted an observational study of 153 unselected pwT1D, and found that the higher the CGM hypoglycaemia events over 6 days, the higher the fraction of asymptomatic sensor-detected hypoglycaemic episodes and the higher the risk of SH.²⁹ In contrast, Choudhary and colleagues (2010) found no

identifiable CGM differences in hypoglycaemia between pwT1D with and without IAH.⁷⁵ A post-hoc analysis of the DIAMOND and HypoDE trials showed that CGM-derived low blood glucose index (LBGI) and %time <3.9 mmol/L (AUC 0.68–0.75) could significantly predict future SH, yet time <3.0 mmol/L demonstrated mixed results.⁷⁶ Findings from post-hoc analysis of the ABCD FreeStyle Libre Audit, including paired TBR, SH and Gold score data from 5029 pwT1D started on CGM, showed that TBR alone had a weak correlation with IAH and SH, only marginally better than random guessing (AUC 0.597 and 0.598 respectively).⁷⁷ However, TBR cutoffs of 3.35% for IAH and 3.95% for SH, yielded high negative predictive values of 85% and 97% respectively, indicating that if TBR is below these cutoffs, there is a low chance of IAH or SH. Gold score alone had an AUC of 0.734 for predicting SH providing some evidence of its validity in the CGM era. Adding TBR to the Gold score did not confer much benefit, only marginally increasing the AUC to 0.747.

Studies have also addressed whether CGM-detected hypoglycaemia contributes to reduced defences of SH by attenuating counterregulatory responses. Two recent hyperinsulinaemic-hypoglycaemic clamp studies concluded that CGM-derived TBR can predict impaired adrenaline response to hypoglycaemia in pwT1D.^{78,79} Thomas et al. (2024) initiated 22 pwT1D on 14 days of blinded CGM, prior to a hyperinsulinaemic-hypoglycaemic clamp. They found that CGM TBR was associated with a reduced adrenaline response ($r = 0.555$, $p = 0.007$), although it should be noted that the TBR values were higher than routinely seen in clinical practice: a third of the %TBR values were above 19%.⁷⁸ In a study of 42 pwT1D comparing 1-week blinded CGM to responses in clamp-induced hypoglycaemia, a negative association between TBR and adrenaline response was also observed,⁷⁹ particularly driven by level 2 hypoglycaemia. Another small study aimed to assess whether the combination of CGM metrics with traditional questionnaires could further increase accuracy.⁶⁶ The authors demonstrated that a Clarke score with a cut-off of ≥ 4 has excellent sensitivity in detecting absent symptom response in clamp-induced hypoglycaemia of 100% but only had a specificity of 50%. A percentage time <3 mmol/L of $\geq 2.21\%$ had an 89% sensitivity and 73% specificity in predicting a reduced autonomous symptom response. When the Clarke score and time <3 mmol/L of $\geq 2.21\%$ were combined, the sensitivity remained at 89%, but the specificity increased further to 87%. When the Clarke score and time <3.9 mmol/L of $\geq 9.42\%$ were combined, the sensitivity was 78% with a specificity of 93%. However, the %TBR required for these outcomes was higher than the 4% and 1% specified in the consensus guidelines.⁷⁰

Overall, the data on whether CGM can be used to diagnose IAH is mixed requiring further elucidation. It appears there is scope to use TBR as a negative predictor to rule out a diagnosis of IAH. A better solution may be to combine TBR with IAH questionnaire scores, to increase the specificity of these already sensitive tests. Recent data has also shown how TBR can be used to predict future SH risk: TBR <4% confers a very low risk, irrespective of awareness status, yet only at much higher values (above 9%) does the TBR correlate with increased risk. The increased risk associated with higher TBR is amplified by impaired awareness as conceptually illustrated in Figure 5.




FIGURE 5 An illustration of risk of severe hypoglycaemia by awareness status and percentage time below range. Created with BioRender.com.

5 | THE CHALLENGE OF ASSESSING IAH WITH CONCURRENT USE OF CGM

The use of CGM poses a number of challenges in how pwT1D and T2D answer the questionnaires, which predate the advent of CGM and AID systems. With threshold and predictive alarms, the person with diabetes may experience more hypoglycaemia via an alert or alarm at a glucose higher than when they would typically experience symptoms so they may not be sure of what symptoms they would experience. The structure of the questions in the IAH questionnaires fails to differentiate between technological awareness (sensor alarms) and physiological awareness (physical symptoms) of hypoglycaemia. Furthermore, technological advances have affected the clinical presentation of IAH: use of CGM reduces the frequency of SH without necessarily restoring the counter-regulation response in people with IAH⁸⁰ and AID systems have been shown to prevent nocturnal hypoglycaemic episodes.⁸¹ The Clarke score is particularly susceptible to change in SH frequency, even when symptomatic awareness has not improved.⁵⁵ As a result, these tools may not be as suitable for discriminating impaired awareness in the modern CGM era, unless they are adapted or are further validated in future studies. Allaying some of these theoretical concerns, a few small studies have shown that the Clarke and Gold scores still correlate with symptom response in clamp studies and with frequency of SH, even with CGM use.^{66,77} However, it is an area where there remains a lack of robust evidence.

Another key question is the relative importance of sensor-detected hypoglycaemia (SDH) compared with person-reported hypoglycaemia (PRH). The recently published HypoMETRICS observational study addressed this question in pwT1D and insulin-treated T2D.⁸² The authors showed that SDH alone did not affect the daily functioning of participants whereas PRH (with or without SDH) was significantly associated with changes in daily functioning. Furthermore, it found that over half of SDH events (at thresholds of 3.9 and 3.0 mmol/L) were asymptomatic, even below 3 mmol/L in people deemed to have normal awareness, and conversely that many symptomatic hypoglycaemic episodes occur above 3.9 mmol/L.⁸³ In a study using CGM sensors in those without diabetes, Shah et al. (2019) demonstrated that 28% of people without diabetes also experience SDH.⁸⁴ There are also questions about the accuracy of CGM in the hypoglycaemic range: CGM has been shown to significantly overestimate the glucose level in the hypoglycaemic range, by 19% compared

with arterialised glucose readings ($p < 0.001$), albeit with hyperinsulinaemia in an experimental hypoglycaemic clamp setting.⁸⁵ However, CGM is a useful tool to identify glucose trends, and provides more comprehensive data than single capillary blood readings, which may not reflect the hypoglycaemic nadir nor provide data on before and after a hypoglycaemic event. Continuous data collection reduces the impact of recall bias when assessing prior hypoglycaemia. The HypoMETRICS app, which was used to survey self-detected hypoglycaemia three times a day for the HypoMETRICS study, has also shown high completion rates and to be acceptable to participants, while allowing real-time reporting of episodes, and therefore, might become a future research or even clinical tool to explore the real-world impact of hypoglycaemia.⁸⁶

6 | DEVELOPING A CLINICAL APPROACH TO IMPAIRED AWARENESS OF HYPOGLYCAEMIA AND RISK OF SEVERE HYPOGLYCAEMIA

Evaluation of the current evidence has demonstrated the strengths and weaknesses of the tools available to the clinician assessing IAH and the risk of SH. Despite the limitations of the evidence including lack of complete validation in the presence of new technologies, and the unclear accuracy of CGM metrics to predict future SH, these tools remain useful in clinical practice. Current research demonstrates that combining different clinical metrics gives a more accurate risk assessment than one tool alone.⁶⁶ Nuance is required when examining CGM data, beyond the headline metrics of the ambulatory glucose profile, to carefully examine all episodes of hypoglycaemia. These can correlate with problematic behaviours which should be sought via a broader holistic clinical assessment.⁷² We suggest a combination approach with equal weight given to multiple factors, in the absence of clear superiority of one measure over the others (Figure 6).




FIGURE 6 A clinical approach to risk assessment of severe hypoglycaemia. Created with [BioRender.com](https://www.biorender.com/). IAH—Impaired Awareness of Hypoglycaemia, CGM—Continuous Glucose Monitoring.

7 | CONCLUSION AND QUESTIONS FOR THE FUTURE

Despite the arrival of new technologies such as CGM and AID, SH remains an important challenge in people living with diabetes. IAH continues to increase the risk of SH despite these new interventions. Where episodes of SH persist despite these treatments, clinical assessment is important to identify people who would benefit from structured education programmes, psychoeducational interventions and rescue treatment with islet cell transplants. The introduction of CGM and alarms indicating hypoglycaemia and impending hypoglycaemia has changed the assessment of SH by reducing its incidence. CGM metrics alone do not appear sufficiently accurate to predict future episodes of SH but are useful when used in combination with other measures. Questionnaire methods of diagnosing IAH have existed since the 1990s and are still used as the primary method of diagnosis. They have previously been validated in terms of prediction of SH, and prediction of symptom and counter-regulatory response to experimental hypoglycaemia. In the era of modern CGM, the cut-offs required for diagnosis and wording of questions are now under review. The different questionnaires and CGM metrics all use arbitrary thresholds, yet a spectrum of disease has been demonstrated in research and in clinical practice. Thus, questions remain over where thresholds are set. The Hypo A-Q questionnaire offers a new measure of IAH with more careful construction and validation, and is the only questionnaire specifically designed to meet FDA PROM standards. A contemporary, well-powered study, comparing all the methods described in this article in the presence of ubiquitous CGM use in people with diabetes with a spectrum of awareness would be beneficial to identify the most accurate tool or combination of tools, which are acceptable to patients and clinicians, to use in modern clinical practice. The CLEAR study (NCT06325202) is expected to address some of these challenges and further elucidate heterogeneity within IAH. A combination of measures, with holistic clinical assessment, is suggested in the absence of a clearly superior tool. Additionally,

further research should be performed in pwT2D, where there have been fewer studies validating the current questionnaires.

ACKNOWLEDGEMENTS

No funding was sourced for this work. We thank our colleagues at our institutions for their support.

CONFLICT OF INTEREST STATEMENT

SAB has received research support from Dexcom and Tandem Diabetes Care. ALL has received speaker fees and/or support to attend conferences from Dexcom and Novo Nordisk and research support from the Association of British Clinical Diabetologists. VK has received support to attend conferences from KelCon GmbH and Eli Lilly. PC has received personal fees from Abbott, Dexcom, Insulet, Medtronic, Novo Nordisk, Lilly, Sanofi, Embecta, Vertex and Roche, and research support from Medtronic, Abbott, Dexcom and Novo Nordisk. EGW has received personal fees from Abbott, AstraZeneca, Dexcom, Eli Lilly, Embecta, Insulet, Medtronic, Novo Nordisk, Roche, Sanofi, Sincare, and Ypsomed and research support from Abbott, Embecta, Insulet, Novo Nordisk, and Sanofi. AI has received research support from Dexcom and Abbott and consultancy fees from Eli Lilly, Boehringer Ingelheim, and AstraZeneca.

PEER REVIEW

The peer review history for this article is available at <https://www.webofscience.com/api/gateway/wos/peer-review/10.1111/dom.16284>.

DATA AVAILABILITY STATEMENT

Data sharing not applicable to this article as no datasets were generated or analysed during the current study.

ORCID

Simon A. Berry  <https://orcid.org/0009-0007-9100-8778>

Alexandros L. Liarakos  <https://orcid.org/0000-0003-1713-3064>

Vaios Koutroukas  <https://orcid.org/0000-0001-6120-8057>

Pratik Choudhary  <https://orcid.org/0000-0001-7635-4735>

Emma G. Wilmot  <https://orcid.org/0000-0002-8698-6207>

Ahmed Iqbal  <https://orcid.org/0000-0002-5648-0539>

REFERENCES

- Cryer PE. Mechanisms of hypoglycemia-associated autonomic failure in diabetes. *N Engl J Med.* 2013;369(4):362-372. doi:10.1056/nejmra1215228
- The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med.* 1993;329(14):977-986. doi:10.1056/nejm199309303291401
- Glucose concentrations of less than 3.0 mmol/L (54 mg/dL) should be reported in clinical trials: a joint position statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care.* 2017;40(1):155-157. doi:10.2337/dc16-2215
- Gagnum V, Stene LC, Jenssen TG, et al. Causes of death in childhood-onset type 1 diabetes: long-term follow-up. *Diabet Med.* 2017;34(1):56-63. doi:10.1111/dme.13114
- Mitrakou A, Ryan C, Veneman T, et al. Hierarchy of glycemic thresholds for counterregulatory hormone secretion, symptoms, and cerebral dysfunction. *Am J Physiol.* 1991;260(1):E67-E74. doi:10.1152/ajpendo.1991.260.1.E67
- Amiel S. Impaired awareness of hypoglycaemia. *Br J Diabetes.* 2022;22(Suppl 1):S26-S31. doi:10.15277/bjd.2022.358
- Heller SR, Cryer PE. Reduced neuroendocrine and symptomatic responses to subsequent hypoglycemia after 1 episode of hypoglycemia in nondiabetic humans. *Diabetes.* 1991;40(2):223-226. doi:10.2337/diab.40.2.223
- Verhulst CEM, Fabricius TW, Teerenstra S, et al. Glycaemic thresholds for counterregulatory hormone and symptom responses to hypoglycaemia in people with and without type 1 diabetes: a systematic review. *Diabetologia.* 2022;65(10):1601-1612. doi:10.1007/s00125-022-05749-8
- Geddes J, Schopman JE, Zammitt NN, Frier BM. Prevalence of impaired awareness of hypoglycaemia in adults with type 1 diabetes. *Diabet Med.* 2008;25(4):501-504. doi:10.1111/j.1464-5491.2008.02413.x
- Schopman JE, Geddes J, Frier BM. Prevalence of impaired awareness of hypoglycaemia and frequency of hypoglycaemia in insulin-treated type 2 diabetes. *Diabetes Res Clin Pract.* 2010;87(1):64-68. doi:10.1016/j.diabres.2009.10.013
- Galassetti P, Mann S, Tate D, et al. Effects of antecedent prolonged exercise on subsequent counterregulatory responses to hypoglycemia. *Am J Physiol.* 2001;280(6):E908-E917. doi:10.1152/ajpendo.2001.280.6.E908
- Jones TW, Porter P, Sherwin RS, et al. Decreased epinephrine responses to hypoglycemia during sleep. *N Engl J Med.* 1998;338(23):1657-1662. doi:10.1056/nejm199806043382303
- Siafarikas A, Johnston RJ, Bulsara MK, O'Leary P, Jones TW, Davis EA. Early loss of the glucagon response to hypoglycemia in adolescents with type 1 diabetes. *Diabetes Care.* 2012;35(8):1757-1762. doi:10.2337/dc11-2010
- Stanley S, Moheet A, Seaquist ER. Central mechanisms of glucose sensing and Counterregulation in defense of hypoglycemia. *Endocr Rev.* 2019;40(3):768-788. doi:10.1210/er.2018-00226
- Nwokolo M, Amiel SA, O'Daly O, et al. Impaired awareness of hypoglycemia disrupts blood flow to brain regions involved in arousal and decision making in type 1 diabetes. *Diabetes Care.* 2019;42(11):2127-2135. doi:10.2337/dc19-0337
- Bilal A, Yi F, Whitaker K, Igudesman D, Pratley R, Casu A. Impaired awareness of hypoglycemia in older adults with type 1 diabetes: a post hoc analysis of the WISDM study. *Diabetes Care.* 2024;47(7):1202-1210. doi:10.2337/dc24-0201
- Hernar I, Strandberg RB, Nilsen RM, et al. Prevalence and risk factors for impaired awareness of hypoglycaemia: a registry-based study of 10202 adults with type 1 diabetes in Norway. *Diabet Med.* 2025;42(3):e15480. doi:10.1111/dme.15480. Epub 2024 Nov 15.
- Fanelli CG, Epifano L, Rambotti AM, et al. Meticulous prevention of hypoglycemia normalizes the glycemic thresholds and magnitude of Most of neuroendocrine responses to, symptoms of, and cognitive function during hypoglycemia in intensively treated patients with short-term IDDM. *Diabetes.* 1993;42(11):1683-1689. doi:10.2337/diab.42.11.1683
- Dagogo-Jack S, Rattarasarn C, Cryer PE. Reversal of hypoglycemia unawareness, but not defective glucose Counterregulation, in IDDM. *Diabetes.* 1994;43(12):1426-1434. doi:10.2337/diab.43.12.1426
- Cranston I, Lomas J, Amiel SA, Maran A, Macdonald I. Restoration of hypoglycaemia awareness in patients with long-duration insulin-dependent diabetes. *Lancet.* 1994;344(8918):283-287. doi:10.1016/s0140-6736(94)91336-6
- Fanelli C, Pampanelli S, Epifano L, et al. Long-term recovery from unawareness, deficient counterregulation and lack of cognitive dysfunction during hypoglycaemia, following institution of rational,

- intensive insulin therapy in IDDM. *Diabetologia*. 1994;37(12):1265-1276. doi:10.1007/bf00399801
22. Gold AE, Macleod KM, Frier BM. Frequency of severe hypoglycemia in patients with type 1 diabetes with impaired awareness of hypoglycemia. *Diabetes Care*. 1994;17(7):697-703. doi:10.2337/diacare.17.7.697
 23. Clarke WL, Cox DJ, Gonder-Frederick LA, Julian D, Schlundt D, Polonsky W. Reduced awareness of hypoglycemia in adults with IDDM: a prospective study of hypoglycemic frequency and associated symptoms. *Diabetes Care*. 1995;18(4):517-522. doi:10.2337/diacare.18.4.517
 24. Hopkins D, Lawrence I, Mansell P, et al. Improved biomedical and psychological outcomes 1 year after structured education in flexible insulin therapy for people with type 1 diabetes. *Diabetes Care*. 2012; 35(8):1638-1642. doi:10.2337/dc11-1579
 25. Speight J, Barendse SM, Singh H, et al. Characterizing problematic hypoglycaemia: iterative design and preliminary psychometric validation of the Hypoglycaemia awareness questionnaire (HypoA-Q). *Diabetic Med*. 2016;33(3):376-385. doi:10.1111/dme.12824
 26. Pedersen-Bjergaard U, Pramming S, Thorsteinsson B. Recall of severe hypoglycaemia and self-estimated state of awareness in type 1 diabetes. *Diabetes Metab Res Rev*. 2003;19(3):232-240. doi:10.1002/dmrr.377
 27. Bailey TS, Alva S. Landscape of continuous glucose monitoring (CGM) and integrated CGM: accuracy considerations. *Diabetes Technol Ther*. 2021;23(S3):S-5-S-11. doi:10.1089/dia.2021.0236
 28. Pühr SDM, Welsh JB, Parker AS, Walker T, Price DA. Real-world hypoglycemia avoidance with a continuous glucose monitoring system's predictive low glucose alert. *Diabetes Technol Ther*. 2019;21(4): 155-158. doi:10.1089/dia.2018.0359
 29. Henriksen MM, Andersen HU, Thorsteinsson B, Pedersen-Bjergaard U. Hypoglycemic exposure and risk of asymptomatic hypoglycemia in type 1 diabetes assessed by continuous glucose monitoring. *J Clin Endocrinol Metabol*. 2018;103(6):2329-2335. doi:10.1210/jc.2018-00142
 30. Hepburn DA, MacLeod KM, Pell ACH, Scougal IJ, Frier BM. Frequency and symptoms of Hypoglycaemia experienced by patients with type 2 diabetes treated with insulin. *Diabet Med*. 1993;10(3): 231-237. doi:10.1111/j.1464-5491.1993.tb00050.x
 31. Lin YK, Richardson CR, Dobrin I, et al. Beliefs around hypoglycemia and their impacts on hypoglycemia outcomes in individuals with type 1 diabetes and high risks for hypoglycemia despite using advanced diabetes technologies. *Diabetes Care*. 2022;45(3):520-528. doi:10.2337/dc21-1285
 32. Baxter F, Baillie N, Dover A, Stimson RH, Gibb F, Forbes S. A cross-sectional questionnaire study: impaired awareness of hypoglycaemia remains prevalent in adults with type 1 diabetes and is associated with the risk of severe hypoglycaemia. *PLoS One*. 2024;19(6): e0297601. doi:10.1371/journal.pone.0297601
 33. Ali N, Hamdaoui E, Schouwenberg BJ, Tack CJ, De Galan BE. Fall in prevalence of impaired awareness of hypoglycaemia in individuals with type 1 diabetes. *Diabet Med*. 2023;40(4):e15042. doi:10.1111/dme.15042
 34. Wellens MJ, Vollenbrock CE, Dekker P, et al. Residual C-peptide secretion and hypoglycemia awareness in people with type 1 diabetes. *BMJ Open Diabetes Res Care*. 2021;9(1):e002288. doi:10.1136/bmjdr-2021-002288
 35. Sherr JL, Laffel LM, Liu J, et al. Severe hypoglycemia and impaired awareness of hypoglycemia persist in people with type 1 diabetes despite use of diabetes technology: results from a cross-sectional survey. *Diabetes Care*. 2024;47(6):941-947. doi:10.2337/dc23-1765
 36. Cabré C, Colungo C, Vinagre I, Jansà M, Conget I. Frequency and awareness of hypoglycemia in patients with type 2 diabetes treated with two or more insulin injections in primary care outpatient clinics. *Prim Care Diabetes*. 2020;14(2):168-172. doi:10.1016/j.pcd.2019.08.001
 37. Van Meijel LA, De Vegt F, Abbink EJ, et al. High prevalence of impaired awareness of hypoglycemia and severe hypoglycemia among people with insulin-treated type 2 diabetes: the Dutch diabetes pearl cohort. *BMJ Open Diabetes Res Care*. 2020;8(1):e000935. doi:10.1136/bmjdr-2019-000935
 38. Ang LC, Bee YM, Goh S-Y, Teh MM. New insights into the currently available questionnaire for assessing impaired awareness of hypoglycaemia (IAH) among insulin-treated type 2 diabetes- a key risk factor for hypoglycaemia. *Diabetes Epidemiol Metab*. 2023;10:100136. doi:10.1016/j.deman.2023.100136
 39. Hermanns N, Heinemann L, Freckmann G, Waldenmaier D, Ehrmann D. Impact of CGM on the management of hypoglycemia problems: overview and secondary analysis of the HypoDE study. *J Diabetes Sci Technol*. 2019;13(4):636-644. doi:10.1177/1932296819831695
 40. Charleer S, De Block C, Nobels F, et al. Sustained impact of real-time continuous glucose monitoring in adults with type 1 diabetes on insulin pump therapy: results after the 24-month RESCUE study. *Diabetes Care*. 2020;43(12):3016-3023. doi:10.2337/dc20-1531
 41. Deshmukh H, Willmot EG, Gregory R, et al. Effect of flash glucose monitoring on glycemic control, hypoglycemia, diabetes-related distress, and resource utilization in the Association of British Clinical Diabetologists (ABCD) Nationwide audit. *Diabetes Care*. 2020;43(9): 2153-2160. doi:10.2337/dc20-0738
 42. Sølvik UØ, Cooper JG, Løvaas KF, et al. A register-based study describing time trends in risk factor control and serious hypoglycaemia together with the effects of starting continuous glucose monitoring in people with type 1 diabetes in Norway. *Diabet Med*. 2024; 41(7):e15335. doi:10.1111/dme.15335
 43. Madar H, Wu Z, Bandini A, et al. Influence of severe hypoglycemia definition wording on reported prevalence in adults and adolescents with type 1 diabetes: a cross-sectional analysis from the BETTER patient-engagement registry analysis. *Acta Diabetol*. 2022;60(1):93-100. doi:10.1007/s00592-022-01987-9
 44. Chantzaras A, Yfantopoulos J. Evaluating the incidence and risk factors associated with mild and severe hypoglycemia in insulin-treated type 2 diabetes. *Value in Health Regional Issues*. 2022;30:9-17. doi:10.1016/j.vhri.2021.10.005
 45. Pedersen-Bjergaard U, Pramming S, Heller SR, et al. Severe hypoglycaemia in 1076 adult patients with type 1 diabetes: influence of risk markers and selection. *Diabetes Metab Res Rev*. 2004;20(6):479-486. doi:10.1002/dmrr.482
 46. Heller SR, Peyrot M, Oates SK, Taylor AD. Hypoglycemia in patient with type 2 diabetes treated with insulin: it can happen. *BMJ Open Diabetes Res Care*. 2020;8(1):e001194. doi:10.1136/bmjdr-2020-001194
 47. Khunti K, Alsifri S, Aronson R, et al. Rates and predictors of hypoglycaemia in 27585 people from 24 countries with insulin-treated type 1 and type 2 diabetes: the global HAT study. *Diabetes Obes Metab*. 2016;18(9):907-915. doi:10.1111/dom.12689
 48. Pedersen-Bjergaard U, Færch L, Allingbjerg M-L, Agesen R, Thorsteinsson B. The influence of new European Union Driver's license legislation on reporting of severe hypoglycemia by patients with type 1 diabetes. *Diabetes Care*. 2015;38(1):29-33. doi:10.2337/dc14-1417
 49. Lin YK, Hung M, Sharma A, et al. Impaired awareness of hypoglycemia continues to be a risk factor for severe hypoglycemia despite the use of continuous glucose monitoring system in type 1 diabetes. *Endocr Pract*. 2019;25(6):517-525. doi:10.4158/ep-2018-0527
 50. Seyed Ahmadi S, Westman K, Pivodic A, et al. The association between HbA1c and time in hypoglycemia during CGM and self-monitoring of blood glucose in people with type 1 diabetes and

- multiple daily insulin injections: a randomized clinical trial (GOLD-4). *Diabetes Care*. 2020;43(9):2017-2024. doi:10.2337/dc19-2606
51. Oliver N, Gimenez M, Calhoun P, et al. Continuous glucose monitoring in people with type 1 diabetes on multiple-dose injection therapy: the relationship between glycemic control and hypoglycemia. *Diabetes Care*. 2020;43(1):53-58. doi:10.2337/dc19-0977
 52. Ryan EA, Shandro T, Green K, et al. Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation. *Diabetes*. 2004;53(4):955-962. doi:10.2337/diabetes.53.4.955
 53. Fabricius TW, Verhulst CEM, Kristensen PL, et al. Hyperinsulinaemic-hypoglycaemic glucose clamps in human research: a systematic review of the literature. *Diabetologia*. 2021;64(4):727-736. doi:10.1007/s00125-020-05361-8
 54. Little S, Chadwick T, Choudhary P, et al. Comparison of optimised MDI versus pumps with or without sensors in severe Hypoglycaemia (the Hypo COMPaSS trial). *BMC Endocr Disord*. 2012;12(1):33. doi:10.1186/1472-6823-12-33
 55. Sepúlveda E, Poinhos R, Nata G, et al. Differentiating hypoglycemia awareness status from hypoglycemia experience in tools for measuring impaired awareness of hypoglycemia. *Diabetes Technol Ther*. 2020;22(7):541-545. doi:10.1089/dia.2020.0034
 56. Geddes J, Wright RJ, Zammitt NN, Deary IJ, Frier BM. An evaluation of methods of assessing impaired awareness of hypoglycemia in type 1 diabetes. *Diabetes Care*. 2007;30(7):1868-1870. doi:10.2337/dc06-2556
 57. Ghandi K, Pieri B, Dornhorst A, Hussain S. A comparison of validated methods used to assess impaired awareness of Hypoglycaemia in type 1 diabetes: an observational study. *Diabetes. Therapy*. 2021; 12(1):441-451. doi:10.1007/s13300-020-00965-0
 58. Rubin NT, Seaquist ER, Eberly L, et al. Relationship between hypoglycemia awareness status on Clarke/Gold methods and Counterregulatory response to hypoglycemia. *Journal of the endocrine. Society*. 2022;6(9):bvac107. doi:10.1210/jendso/bvac107
 59. Little SA, Leelarithna L, Walkinshaw E, et al. Recovery of hypoglycemia awareness in long-standing type 1 diabetes: a multicenter 2 × 2 factorial randomized controlled trial comparing insulin pump with multiple daily injections and continuous with conventional glucose self-monitoring (HypoCOMPaSS). *Diabetes Care*. 2014;37(8):2114-2122. doi:10.2337/dc14-0030
 60. Pedersen-Bjergaard U, Høj-Hansen T, Thorsteinsson B. An evaluation of methods of assessing impaired awareness of hypoglycemia in type 1 diabetes. *Diabetes Care*. 2007;30(11):e112. doi:10.2337/dc07-1181
 61. Pedersen-Bjergaard U, Færch L, Thorsteinsson B. The updated Pedersen-Bjergaard method for assessment of awareness of hypoglycaemia in type 1 diabetes. *Dan Med J*. 2022;69(9):A01220041.
 62. Sejling AS, Schouwenberg B, Færch LH, Thorsteinsson B, De Galan BE, Pedersen-Bjergaard U. Association between hypoglycaemia and impaired hypoglycaemia awareness and mortality in people with type 1 diabetes mellitus. *Diabet Med*. 2016;33(1):77-83. doi:10.1111/dme.12810
 63. Matus A, Flatt AJ, Peleckis AJ, Dalton-Bakes C, Riegel B, Rickels MR. Validating and establishing a diagnostic threshold for the hypoglycemia awareness questionnaire impaired awareness subscale. *Endocr Pract*. 2023;29(10):762-769. doi:10.1016/j.eprac.2023.08.004
 64. Verhulst CEM, Fabricius TW, Nefs G, et al. Consistent effects of hypoglycemia on cognitive function in people with or without diabetes. *Diabetes Care*. 2022;45(9):2103-2110. doi:10.2337/dc21-2502
 65. Senior PA, Bellin MD, Alejandro R, et al. Consistency of quantitative scores of hypoglycemia severity and glycemic lability and comparison with continuous glucose monitoring system measures in long-standing type 1 diabetes. *Diabetes Technol Ther*. 2015;17(4):235-242. doi:10.1089/dia.2014.0289
 66. Flatt AJCE, Peleckis AJ, Dalton-Bakes C, et al. Evaluation of Clinical Metrics for Identifying Defective Physiologic Responses to Hypoglycemia in Long-Standing Type 1 Diabetes. *Diabetes Technol Ther*. 2022;24(10):737-748. doi:10.1089/dia.2022.0103
 67. U.S. Food & Drug Administration (FDA). Patient-reported outcome measures: use in medical product development to support labeling claims. FDA-2006-D-0362. 2009.
 68. Henao-Carrillo DC, Sierra-Matamoros FA, Carrillo Algarra AJ, García-Lugo JP, Hernández-Zambrano SM. Validation of the hypoglycemia awareness questionnaire to assess hypoglycemia awareness in patients with type 2 diabetes treated with insulin. *Diabetes Metab Syndr Clin Res Rev*. 2023;17(12):102917. doi:10.1016/j.dsx.2023.102917
 69. Divilly P, Zaremba N, Mahmoudi Z, et al. Hypo-METRICS: Hypoglycaemia—MEasurement, Thresholds and Impacts—A multi-country clinical study to define the optimal threshold and duration of sensor-detected hypoglycaemia that impact the experience of hypoglycaemia, quality of life and health economic o. *Diabet Med*. 2022; 39(9):e14892. doi:10.1111/dme.14892
 70. Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. *Diabetes Care*. 2019; 42(8):1593-1603. doi:10.2337/dci19-0028
 71. Thabit H, Schofield J, Leelarithna L. Beware the pitfalls of time below range. *Diabet Med*. 2023;40(11):e15124. doi:10.1111/dme.15124
 72. Cook AJ, Dubose SN, Foster N, et al. Cognitions associated with hypoglycemia awareness status and severe hypoglycemia experience in adults with type 1 diabetes. *Diabetes Care*. 2019;42(10):1854-1864. doi:10.2337/dc19-0002
 73. Vieira IH, Barros LM, Baptista CF, Melo M, Rodrigues DM, Paiva IM. Hypoglycemia unawareness in type 1 diabetes patients using intermittent continuous glucose monitoring: identification of risk factors and glycemic patterns. *Diabetes Metab Syndr Obes*. 2022;16(6): 102525. doi:10.1016/j.dsx.2022.102525
 74. Lin YK, Groat D, Chan O, et al. Associations between the time in hypoglycemia and hypoglycemia awareness status in type 1 diabetes patients using continuous glucose monitoring systems. *Diabetes Technol Ther*. 2020;22(11):787-793. doi:10.1089/dia.2020.0016
 75. Choudhary P, Geddes J, Freeman JV, Emery CJ, Heller SR, Frier BM. Frequency of biochemical hypoglycaemia in adults with type 1 diabetes with and without impaired awareness of hypoglycaemia: no identifiable differences using continuous glucose monitoring. *Diabet Med*. 2010;27(6):666-672. doi:10.1111/j.1464-5491.2010.03006.x
 76. Hermanns N, Ehrmann D, Heinemann L, Freckmann G, Waldenmaier D, Calhoun P. Real-time continuous glucose monitoring can predict severe hypoglycemia in people with type 1 diabetes: combined analysis of the HypoDE and DIAMOND trials. *Diabetes Technol Ther*. 2022;24(9):603-610. doi:10.1089/dia.2022.0130
 77. Deshmukh H, Wilmot EG, Choudhary P, et al. Time below range and its influence on hypoglycemia awareness and severe hypoglycemia: insights from the Association of British Clinical Diabetologists Study. *Diabetes Care*. 2025;dc241833. doi:10.2337/dc24-1833
 78. Thomas RL, Boeder SC, Hamidi V, Giovannetti ER, Gregory JM, Pettus JH. Continuous glucose monitoring time below range predicts impaired epinephrine response to hypoglycemia in patients with type 1 diabetes. *Diabetes Care*. 2024;47(5):e39-e41. doi:10.2337/dc23-2501
 79. Svensson CH, Fabricius TW, Verhulst CEM, et al. Association between recent exposure to continuous glucose monitoring-recorded hypoglycaemia and counterregulatory and symptom responses to subsequent controlled hypoglycaemia in people with type 1 diabetes. *Diabetes Obes Metab*. 2024;26(8):3213-3222. doi:10.1111/dom.15649
 80. Rickels MR, Peleckis AJ, Dalton-Bakes C, et al. Continuous glucose monitoring for hypoglycemia avoidance and glucose Counterregulation in long-standing type 1 diabetes. *J Clin Endocrinol Metabol*. 2018; 103(1):105-114. doi:10.1210/jc.2017-01516

81. Anderson SM, Buckingham BA, Breton MD, et al. Hybrid closed-loop control is safe and effective for people with type 1 diabetes who are at moderate to high risk for hypoglycemia. *Diabetes Technol Ther*. 2019;21(6):356-363. doi:[10.1089/dia.2019.0018](https://doi.org/10.1089/dia.2019.0018)
82. S holm U, Broadley M, Zaremba N, et al. The impact of hypoglycaemia on daily functioning among adults with diabetes: a prospective observational study using the Hypo-METRICS app. *Diabetologia*. 2024;67:2160-2174. doi:[10.1007/s00125-024-06233-1](https://doi.org/10.1007/s00125-024-06233-1)
83. Divilly P, Martine-Edith G, Zaremba N, et al. Relationship between sensor-detected hypoglycemia and patient-reported hypoglycemia in people with type 1 and insulin-treated type 2 diabetes: the Hypo-METRICS study. *Diabetes Care*. 2024;47:1769-1777. doi:[10.2337/dc23-2332](https://doi.org/10.2337/dc23-2332)
84. Shah VN, Dubose SN, Li Z, et al. Continuous glucose monitoring profiles in healthy nondiabetic participants: a multicenter prospective study. *J Clin Endocrinol Metabol*. 2019;104(10):4356-4364. doi:[10.1210/jc.2018-02763](https://doi.org/10.1210/jc.2018-02763)
85. Farrell CM, Mcneilly AD, Hapca SM, Mccrimmon RJ. Real-time continuous glucose monitoring during a Hyperinsulinemic-hypoglycemic clamp significantly underestimates the degree of hypoglycemia. *Diabetes Care*. 2020;43(10):e142-e143. doi:[10.2337/dc20-0882](https://doi.org/10.2337/dc20-0882)
86. S holm U, Broadley M, Zaremba N, et al. Psychometric properties of an innovative smartphone application to investigate the daily impact of hypoglycemia in people with type 1 or type 2 diabetes: the Hypo-METRICS app. *PLoS One*. 2023;18(3):e0283148. doi:[10.1371/journal.pone.0283148](https://doi.org/10.1371/journal.pone.0283148)

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Berry SA, Liarakos AL, Koutroukas V, Choudhary P, Wilmot EG, Iqbal A. The challenge of assessing impaired awareness of hypoglycaemia in diabetes in the era of continuous glucose monitoring: A narrative review of evidence and translation into clinical practice. *Diabetes Obes Metab*. 2025;1-14. doi:[10.1111/dom.16284](https://doi.org/10.1111/dom.16284)